This study is one of few to assess the genetic diversity of crops in an agroecosystem over several years. Researchers analysed the genetic makeup of oilseed rape plants within and outside crop fields over four years. They found similarity between cultivars of field plants in one year and those of feral plants (unplanted) in the following year. They also found persistence of the cultivars within the feral plants, which suggests that feral populations with genetically modified (GM) traits might result from persistent GM traits within field seed banks. The researchers say their findings could aid impact assessments of GM crops.

New research suggests that feral oilseed rape poses little risk of contaminating crops, but if the oilseed is genetically modified (GM), it could be a minor source of GM traits in weeds. Throughout Europe, feral oilseed rape is now widespread on waysides and wasteland, making it potentially more problematic than some other crops, such as maize, which do not easily establish feral populations.

A new study from Poland has confirmed the potential of fungal Trichoderma species to control diseases of oilseed rape crops. The use of Trichoderma can reduce the growth of disease-causing oilseed rape pathogens, which may allow a decrease in the use of harmful pesticides.

Disease-fighting microbes, insect-eating predators and mating-disrupting pheromones are among the tools listed in a new review of methods that can be used to reduce synthetic pesticide use on grapevines in Europe. Using these alternative methods can reduce the environmental and health risks associated with chemical pesticides, but further development is required to make them attractive to growers.

As construction begins on a 32-story prefab tower here in the U.S., Broad Sustainable Building Corp. is preparing for a similar project in China that will resul

Units in Dubai's wind- and solar-powered Dynamic Tower will sell for $30M — Dramamine not included.

The 2017 Beaujolais Nouveau has just been released, fulfilling the destiny of many French gamay grapes.

Uncle Ben meets 'Blade Runner' in this wild vertical farming concept that also incorporates aquaculture, wind energy and 'algae facades.'

The longing you feel to get away is ancient, says writer Clemens Arvay, a desire to interact with nature and leave behind the material world.

De Bos Rosé is handpicked, fair trade accredited and made from 47 different varietals of grapes.

Recent research finds that grapefruit juice stems weight loss by 18 percent in mice and may be as effective as diabetes drugs.

Bonterra: Our Organic Grapes Make Better Wine

GRIND LINE Hockey Camps offer the 2012 Summer Series: ALL Girls/Women's 7/16th-20th; ELITE AAA Camp 8/6th-10th; ALL SKILLS Camp 8/21st-24th. Information and Registration found on www.coresportsfitness.com.

Free Introductory Youth Hockey Program - Where Every Aspiring Young Player Experiences the Excitement of Hockey

Therapy by Clinton Opens inside Salon & Spa Galleria and Offers 20% off to New and Returning Clients

A panel of seven Colorado doctors, including Chief Veterinary Officer of Folium Biosciences, Dr. Robert J. Silver, provided a packed lecture hall, with the most up to date information on using cannabis with animals.

New generation CIP system designed for wineries and other sanitary process environments with fixed tanks that require mobile solutions

Texas Expansion Continues for Rapidly Growing Global Coworking Space

Bernstein joins a select group of only six CEOs, Presidents, Owners and Managers selected as a Best Boss in St. Louis

Named a Future 50 company by St. Louis Small Business Monthly representing one of the fastest growing companies in the St. Louis region.

Resveratrol powers a pocket-sized solution for healing and protecting lips

Unification and Integration is key in the fragmented digital health ecosystem

Prüvit Introduces Summer Collection

Seasoned Beauty Pro Offers Microblading and Eyelash Extensions

Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors will be delighted, with the company turning in some strong numbers...

Margaret Parker, MD, MCCM, speaks with George P. Liao, MD and Charles S. Cox, MD

Authorities say details on his capture are forthcoming,

From the museum of Sankey diagrams, here is a black&white classic. This Sankey process diagram for rapeseed oil production is taken from the year 2002 dissertation ‘Simultane Öl- und Proteingewinnung bei Raps’ (Simultaneous oil and protein production from rapeseed) by Andreas Waesche, Berlin Technical University.
[See image gallery at www.sankey-diagrams.com]
Flows are in kilograms per ton of rapeseed input. Black is the water fraction, dark gray is oil, and light gray is oil free dry matter. Rapeseed husks, filtered matter and liquid rejects branch out on arrows to the right. Extract from the T4 separation stage (‘Extrakt als Ruckfuhrung’) is fed back into the second node although this loop is not shown here.

The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C and/or RSK disorders, including diseases and disorders mediated by GPCRs and/or RSKs.

Dental compositions are provided comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof: wherein n is an integer from about 2 to about 5.

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyridyl-amino-pyrazine carbonitrile compounds that, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; and (e) ionizing radiation.

A pharmaceutical composition comprising lectins is anti-tumorigenic and anti-viral, bacterial or protozoan. The composition, termed BiOmune is also useful for imaging, diagnosis and therapy of cancer.

This invention describes the use of S-abscisic acid (S-ABA) and ethylene producing-agents such as ethephon to synergistically improve red color in grapes and to alter the sensory characteristics of wine.

The invention is a method of processing tarry or resinous liquids. Tarry liquids include wet scrubber liquids containing tars and chars derived from gasification, pyrolysis or drying of biomass. Resinous liquids include those derived from processing coniferous biomass. Tarry or resinous liquid is processed by a horizontal axis centrifuge having a discharge chamber containing a scraper to prevent centrifuge clogging or fouling. The removed tar and char can be used as solid fuel or recycled to the gasification or pyrolysis process. Polymers, for instance cationic polymers, can be added to the tarry or resin containing liquid prior to centrifugation to assist in solids/liquids separation. Removed resin can be recycled for further use. Tar, char or resin depleted wet scrubber liquid can be recycled for further use or more easily treated prior to disposal.

The present invention relates to a system and method for using the system. In particular, the present invention relates to an application, executable by a processing device to assess the organization of a non-nutritive suck (NNS) pattern of a patient and to entrain an organized NNS pattern in the patient. The software system receives data from an orofacial stimulation appliance to assess the patient's natural NNS pattern and generates a precise therapeutic pulse profile that is actuated as a tactile stimulus via the orofacial stimulation appliance to entrain an organized NNS pattern.

A portable hydro massage device for submersion in a body of water containing a female user, i.e. a bathtub, provides a local massage to the labium region and a focused stimulant to the female user's clitoris thereby resulting in a superior sensation to the entire body promoting an overall euphoric state and calming effect. The apparatus employs a saddle shaped housing, where the buttocks are placed, and a saddle horn for controlling the stimulus. Disposed within the midsection of the saddle horn is a hydro jet with a driven flow from a circulating water pump that draws suction from the main body of water. The hydro jet is adjustable in pressure and a method is provided for aeration of the water discharged to allow for a rhythmic pulsation effect. The saddle horn may be held and the lower body positioned as needed to focus the discharged stream from the hydro jet to the desired point of the pelvic region.

A foot rest including: a foot receptacle, the foot receptacle including a first portion and a second portion, and wherein the first portion intersects the second portion; a cross-member disposed on a first side of the first portion; and a bucket connector disposed on the first side of the first portion of the foot receptacle, wherein the cross-member is proximate an end of the first portion and the bucket connector is distal to the end of the first portion.

The present invention features compounds having the Formula (Ia) and (Ib) (e.g., a compound of any of Formulas ((Ia-2)-(Ia-21)), including other tautomers, stereoisomers, E/Z stereoisomers, prodrugs, pharmaceutically acceptable salts, and compositions thereof. The invention also features methods for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient by administering an effective amount of a compound of Formula (Ia) or (Ib). The invention also features a method for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient that includes administering to a patient in need thereof an effective amount of a compound of Formula (IIa) or (IIb) (e.g., a compound of any of Formulas ((IIa-2)-(IIa-6)). The compounds described herein (e.g., a compound of Formulas (Ia), (Ib), (IIa), or (IIb)) can also be used as anticonvulsants.

Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

Intrapersonal communication systems and methods that provide an optical digital signal link between two or more local devices are disclosed. In some embodiments, the system includes a first signal converter disposed at a first end of the optical digital signal link and configured to convert between electrical digital signals from a first local device and optical digital signals from the optical digital signal link. The system can include an optical connector having a non-contact portion configured to couple optical digital signals between the first signal converter and the optical digital signal link across a gap. The system can include a second signal converter disposed at a second end of the optical digital signal link and configured to convert between electrical digital signals from the second local device and optical digital signals from the optical digital signal link.

A therapeutic compression apparatus having a primary wrap, a foot wrap and a stirrup is provided. The primary wrap encircles a first portion of a leg and applies compression thereto. The foot wrap encircles at least a portion of the foot and applies compression thereto. The foot wrap may be integrated with the stirrup, detachably connected or provided separately. The compression apparatus may be configured such that one or more bladders are provided therein. The compression apparatus may include a pressure gauge and pump for controlling an amount of pressure applied to the treatment site. A bladder assembly with a number of fluid bladder configurations is also provided for use within a compression apparatus. The bladder may be configured to provide a gradient pressure profile to the treatment site when filled.

The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

An accommodating intraocular lens (AIOL) includes an optic adapted to produce a trapezoidal phase shift and a plurality of haptics. Each haptic extends from a haptic-optic junction to at least one transverse arm contacting a capsular bag of the eye, and each haptic has sufficient length and rigidity to stretch a capsular bag of the eye to contact ciliary muscles of the eye. The haptic-optic junctions vault the optic forward relative to the haptics and compression of the haptics by the ciliary muscles moves the anterior optic forward. A combined accommodative power produced by the motion of the anterior optic and the trapezoidal phase shift is at least 0.5 Diopters.

The presently disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also provided are methods for using the disclosed compositions for diagnosing (i.e., by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activity.

The present invention is directed to the use of the peptide compound Ac-Arg-Phe-Met-Trp-Met-Arg-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ac-Arg-Phe-Met-Trp-Met-Arg-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilizate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

Plant viral vectors have great potential in rapid production of proteins, but no simple. Here a geminivirus-based system for high-yield and rapid production of oligomeric protein complexes, including virus-like particle (VLP) vaccines and monoclonal antibodies (mAbs) is described. In particular, a single vector that contains two non-competing replicons for transient expression in Nicotiana benthamiana leaves is described. The correct assembly of these subunit proteins into functional oligomeric structures (VLPs or full-size mAb) is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of this technology for producing multiple-subunit protein complexes.

Disclosed is a drug effective in the treatment of fibromyalgia. Basically, the disclosed therapeutic agent was created on the basis of experiments showing improvement in symptoms when etanercept was administered to patients suffering from fibromyalgia. Etanercept is known as a therapeutic agent for rheumatoid arthritis, and the JFIQ score of patients not suffering from fibromyalgia improved considerably in the preferred embodiment. In other words, a therapeutic agent for fibromyalgia is disclosed that contains etanercept as an active ingredient in an effective amount.

Monoclonal antibodies (mAbs) having thyroid stimulating activity (TSAb), especially full or considerably agonistic activity, or thyroid blocking activity (TBAb), which are obtainable by genetic immunization of mice, or fragments (F(ab')2, Fab or Fv) or humanized forms of such monoclonal antibodies or single chain forms (SCA; scFv) of such fragments, which antibodies, or their fragments, compete with bovine TSH for epitopes of the human TSHr, compete with autoantibodies from sera from Graves' patients as well as with autoantibodies from sera from patients harboring blocking autoantibodies for epitopes of the human TSHr, bind to conformational epitopes of the human TSHr located in the first 281 amino acids of the human TSHr, and usually also bind to TSFR receptors (TSHr) from different animals. Various uses of such antibodies, or of peptides corresponding to variable regions of such antibodies, are also described and claimed.